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Background: Vascular cognitive impairment-no dementia (VCIND) refers to the early or mild cognitive impairment
induced by cerebral vascular injury. Research shows that serum total homocysteine (tHcy) level is an independent
risk factor for cerebral vascular disease and may be closely related to cognitive function.Current studies on the tHcy
level in VCIND patients are limited, and the relationship of tHcy with cognitive function remains unclear. This study
aims to investigate the tHcy levels in patients with VCIND and to determine their correlation with cognitive function,
as well as to provide useful clues for preventing and treating VCIND.
Methods: The tHcy, folate, and vitamin B12 levels in 82 patients with VCIND were reviewed retrospectively and
compared with those of 80 stroke patients without cognitive impairment and 69 healthy controls by using the
Montreal Cognitive Assessment (MoCA) scale and the event-related potential P300 to evaluate cognitive function.
Results: The tHcy levels in the VCIND group were higher than those in the other two groups, whereas the folate and
Vitamin B12 levels in the VCIND group were lower than those of the other two groups. The tHcy levels in the stroke
group were higher than those in the control group, and the folate and vitamin B12 levels in the stroke group were
lower than those in the control group. The patients in the VCIND group with high tHcy exhibited lower MoCA scores
and prolonged P300 latency than those in with normal tHcy. Correlation analysis showed that tHcy level is positively
correlated with P300 latency period and negatively correlated with MoCA score.
Conclusion: The tHcy levels were significantly higher and the vitamin B12 and folate levels were significantly lower in
the patients with VCIND than those in the other groups. The high tHcy levels in the VCIND patients may be correlated
with impaired cognitive function.
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Vascular cognitive impairment-no dementia (VCIND)
refers to the early or mild cognitive impairment induced
by cerebral vascular injury. The illness is relatively hidden,
and the degree of cognitive impairment has not yet
reached the diagnostic standard for dementia [1]. VCIND
has an incidence of 39.5% within 1 year after a stroke [2].
Early diagnosis and intervention improve the prognosis of* Correspondence: chengyundingcn@163.com
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unless otherwise stated.VCIND patients, which would otherwise progress into
dementia [3]. Considering its reversibility, VCIND has
become a hot research topic. Research shows that
serum total homocysteine (tHcy) level is an independ-
ent risk factor for cerebral vascular disease [4] and
may be closely related to cognitive function [5]. Current
studies on the tHcy level in VCIND patients are limited,
and the relationship of tHcy with cognitive function
remains unclear. This study aims to investigate the tHcy
levels in patients with VCIND and to determine their
correlation with cognitive function, as well as to provide
useful clues for preventing and treating VCIND.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Participants
From January 2008 to January 2013, 367 new stroke
patients were screened from the Department of Internal
Medicine of the First Affiliated Hospital of PLA General
Hospital. All the stroke patients performed the cognitive
function detection on the post-onset seventh day, first
month, and third month. The patient would be enrolled
in the study when the VCIND inclusion criteria were
met. The detection of related indicators such as folate,
vitamin B12, tHcy, and P300 were completed within 48 h
of enrollment. Among 97 patients that met the VCIND
inclusion criteria, 5 refused to join the experiment, and
10 were not enrolled because they had severe internal
diseases or took medication that would affect tHcy.
Finally, 82 VCIND patients were recruited. Currently,
there are no unified diagnostic criteria of VCIND, and
different studies might use different diagnostic criteria
[3,6]. In our study, VCIND was diagnosed according to
the Rockwood criteria [7] as follows: existing cerebrovas-
cular disease; evidence of cognitive impairment under
neuropsychological assessment; the cognitive impair-
ment occurred within 3 months after stroke; causal rela-
tionship between cerebrovascular disease and cognitive
impairment, excluding other diseases; Hanchinski ischemia
index ≥7; does not conform to the diagnostic criteria for
dementia revised by the United States of America
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV). The exclusion criteria were as
follows: 1) Alzheimer’s patients; 2) other cognitive disor-
ders, mental illness, or hemiplegic aphasia and other dis-
eases that might influence their Montreal score and P300
determination; 3) taking medications that affect tHcy levels
within the past 1 month (such as contraceptives, anti-
epileptic drugs, dopamine drugs, and folate and/or vitamin
B12); 4) the presence of diseases that affect central nervous
system function, such as thyroid disease, severe anemia,
vitamin B12 and folate deficiency, and severe malnutri-
tion, as well as serious liver, kidney, and other organic
diseases.
A total of 80 outpatient and hospitalized stroke pa-
tients were enrolled in the study. Stroke was diagnosed
in accordance with the diagnostic criteria [8], revised by
the 2003 European Stroke Promotion Association, and
was confirmed by MRI scanning and scale detection, as
well as via clinical and cognitive function detection
without cognitive impairment.
The control group consisted of 69 healthy controls who
were also in the First Affiliated Hospital of PLA General
Hospital. The cranial MRI showed no obvious lesion, and
the clinical and cognitive function determination did not
found obvious impairment. This study was conducted in
accordance with the declaration of Helsinki, and was con-
ducted with approval from the Ethics Committee of theFirst Hospital Affiliated to the Chinese PLA General
Hospital. Written informed consent was obtained from all
participants.
Methods
tHcy, folate, and vitamin B12 detection
Fasting venous blood samples (2–3 mL), which were
centrifuged to obtain serum after 30 min, were drawn
from each subject. The tHcy concentration was deter-
mined via enzymatic conversion on a Hitachi 7180 auto-
matic biochemical analyzer (Tokyo, Japan) using a kit
provided by Beijing Nine Strong Biological Technology
Co. Ltd. (Beijing, China). The tHcy levels ranged from 5
to 14 μmol/L. Hyperhomocysteinemia (Hhcy) was de-
fined as a level >14 μmol/L. Vitamin B12 and folate levels
were determined from 3 to 4 mL of venous blood using
an Access automated chemiluminescent microparticle
immunoassay system and the related kit (BECKMAN
Company USA).
Cognitive function tests
Cognitive function was evaluated using the Montreal
Cognitive Assessment scale (MoCA) [9]. The MoCA
includes eight cognitive domains and eleven checking
contents, including visuospatial ability, naming, mem-
ory, attention and calculation, language fluency, ab-
stract thinking, delayed memory, and directional force.
The highest possible score is 30 points. Participants
who had less than 12 years of schooling were given an
additional point in their final score. Higher scores indi-
cate better cognitive function. The impairment assess-
ment criterion was a MoCA <26.
P300 potential measurement
All of the patients underwent a P300 determination
within 48 h by using the British Oxford multimedia
EMG/EP system. In a quiet, shielded room, the partici-
pants were instructed to lie in a supine position, stay
awake, and concentrate. In accordance with International
EEG 10–20 system, recording electrodes were placed in
the central line. The reference electrode was placed on the
right lobe, with frontal grounding. The inter electrode
impedance was <5 KΩ, and the analysis time was 600 ms.
Using Tone Pip stimuli, the probability of the non-target
stimuli (1000 Hz) was set to 80% with a magnitude of
80 dB with gradations. The target stimulus (4000 Hz)
was set to 20% probability with a magnitude of 90 dB
and was interspersed randomly with the non-target
stimuli. The participants were instructed to respond to
the target stimulus by knobbing the key. The instru-
ment automatically recorded the reaction time. The
test was repeated twice, and the mean score was used
in the data analysis.
Table 1 Comparison of serum tHcy (μmol/L), folate
(ng/ml), Vitamin B12 (pg/ml) level between the three
groups (×¯ ± s)
Group Cases (n) tHcy Folate Vitmin B12
VCIND 82 22.14 ± 6.92a 8.01 ± 3.13a 280.85 ± 96.72b
Stroke 80 16.36 ± 7.17d 12.61 ± 3.56c 367.53 ± 127.30c
Control 69 11.86 ± 4.47 16.42 ± 4.91 495.18 ± 102.79
F 13.36 22.81 20.14
P <0.001 <0.001 <0.001
Note: Compared with the other two groups: aP < 0.01, bP < 0.05; compared
with the control group, cP < 0.01, dP < 0.05.
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Data were analyzed using SPSS16.0 software. The recorded
data are expressed as mean ± SD and were compared using
an analysis of variance and a t-test. Nonparametric
Mann–Whitney U tests were performed on the level of
the variable. Count data are expressed as percentages
and compared using a χ2 test. Correlation analysis was
performed via Pearson correlation analysis. Differences
with P <0.05 were considered significant.
Results
Characteristics of the participants
Among the 82 VCIND patients, 73 were inpatients and
9 were outpatients, 49 were male and 33 were female,
and were 41–78 years old, with a mean age of 64 ±
3.14 years. The educational background of the patients
varied, with 14 cases reaching university, 57 cases reach-
ing high school, and 11 cases reaching junior high school.
The National Institutes of Health Stroke Scale (NIHSS)
score was 5.17 ± 1.45, including 35 diabetic, 41 hyperten-
sive, and 29 hyperlipidemic patients.
Of the 80 stroke patients, 51 were male and 29 were
female, with ages ranging from 37 to 77 years and a
mean age of 62 ± 2.79 years. The educational status of
the patients varied as follows: 13 received a university
education, 53 reached high school, and 14 reached
junior high school. Their NIHSS score was 4.77 ± 1.79,
including those of 31 diabetic, 37 hypertensive, and 27
hyperlipidemic patients.
The control group consisted of 42 males and 27
females and included 11 diabetic, 16 hypertensive, and
15 hyperlipidemic patients. Their ages ranged from 41 to
72 years, with a mean age of 61 ± 1.89 years. Their edu-
cational backgrounds were as follows: 17 received a uni-
versity education, 45 reached high school, and 7 reached
junior high school.
Comparison of general states
The three groups did not differ significantly differ in
terms of age (based on the ANOVA, P >0.05), gender,
culture level, and the proportion of patients (based on
the χ2, P >0.05). The VCIND group did not differ from
the stroke group in terms of NIHSS (Mann–Whitney U
test, P >0.05). The VCIND group did not differ signifi-
cantly from the stroke group in terms of the incidence
of diabetes, hypertension, and hyperlipidemia (χ2, P >0.05).
Cognitive function
The VCIND group had significantly lower MoCA scores
(22.81 ± 1.67) than did the other two groups (P <0.01).
The stroke group (27.77 ± 1.03) did not differ signifi-
cantly from the control group (28.23 ± 0.91) in terms of
the total MoCA score (P >0.05).tHcy, folate, and vitamin B12
The tHcy level in the VCIND group was higher than that
of the other two groups. The folate and the vitamin B12
levels in the VCIND group were lower than those in the
other two groups. The tHcy level in the stroke group
was higher than that in the control group, and the folate
and vitamin B12 levels were lower than those in the
control group (Table 1).
Determination of P300
The prolongation of the P300 latency period in the
VCIND group was significantly longer than that in the
stroke and control groups (P <0.01). The prolongation in
the P300 latency period in the stroke group did not dif-
fer significantly from that in the control group (P >0.05).
The three groups did not differ significantly in terms of
P300 amplitude (P >0.05), which is shown in Table 2.
Comparison of MoCA and P300 in the VCIND group
In the VCIND group, 45 patients exhibited Hhcy. The
patients with Hhcy had lower MoCA scores and pro-
longation in the P300 latency period than the patients
with normal tHcy, but the P300 amplitude did not differ
significantly between the groups (Table 3).
Correlation between the tHcy, folate, vitamin B12, P300
latency period, and MoCA in the VCIND group
The tHcy levels in the VCIND group patients were
correlated with their P300 latency periods and MoCA
scores. The tHcy levels were negatively correlated with
MoCA score (r = −0.468, P = 0.038) and were posi-
tively correlated with the P300 latency period (r = 0.740,
P = 0.014). The folate level was positively correlated with
MoCA score (r = 0.509, P = 0.022), and the vitamin
B12 level was positively correlated with MoCA score
(r = 0.588, P = 0.006).
Discussion
tHcy is a thiol-containing amino acid generated from
methionine through in vivo metabolism [10]. Many stud-
ies have shown that high tHcy levels are related to
Table 2 Comparison of the central midline P300 latency
period(MS) and amplitude (μV) between the three groups
(×¯ ± s)
Group Cases (n) P300 latency P300 amplitude
VCIND 82 396.68 ± 76.67a 3.86 ± 0.87
Stroke 80 307.20 ± 50.45 3.80 ± 0.78
Control 69 306.13 ± 70.33 3.83 ± 0.69
F 12.04 0.028
P 0.028 0.973
Note: Compared with the other group, aP < 0.01.
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tHcy on the cognitive functions of VCIND patients has
important clinical significance.
The tHcy levels in the VCIND and stroke groups were
higher than in the normal group. This finding suggests
that tHcy levels are correlated with the pathogenesis of
stroke and is consistent with the current research re-
sults. Specifically, tHcy is an independent risk factor for
cerebral vascular disease [14,15]. The tHcy levels in the
VCIND group were higher than those in the stroke
group, which suggests that cognitive function may be
correlated with tHcy levels.
Previous studies on the relationship between tHcy and
cognitive function differ in their findings [16-18]. Differ-
ent ethnic groups have different apolipoprotein E (ApoE)
genes, which may be associated with cognitive function
[19]. Currently, it is considered that the cognitive im-
pairment caused by tHcy occurs through direct and
indirect paths; the direct path involves increasing glu-
tamate excitotoxicity, thereby reducing neuronal DNA re-
pair capacity and accelerating the formation of oxidative
stress and A β and damage on hippocampal neurons,
which leads to cognitive impairment. The indirect path in-
volves vascular endothelial cell dysfunction and lipid
metabolic disorder, leading to cerebral vascular disease to
cause impairment of cognitive function [20-22]. A certain
randomized, double-blind clinical trial showed that
reduced tHcy could not necessarily improve cognitive
functions [23,24] and, thus, suggested that the current
mechanism of the damages of cognitive functions caused
by tHcy was not entirely clear.Table 3 Comparison of MoCA, P300 between the Hhcy
(tHcy > 14 μmol/L) group and normal tHcy group in
VCIND group (×¯ ± s)
Groups Cases (n) MoCA P300 latency P300
amplitude
Normal tHcy 37 23.71 ± 0.91a 371.67 ± 31.79a 3.88 ± 0.60
Hhcy 45 21.53 ± 1.36 429.07 ± 41.87 3.73 ± 0.78
t 5.041 4.229 0.561
P <0.001 <0.001 >0.05
Note: aP < 0.01.The patients in the VCIND group exhibited higher
tHcy levels than those in the other two groups. Within
the VCIND group, the MoCA score of the patients with
high tHcy was lower than those with normal tHcy. Fur-
thermore, correlation analysis shows that tHcy level is
negatively correlated with MoCA, which suggests that
tHcy levels may be closely associated with impaired
cognitive function.
The P300 event-related potential is an objective elec-
trophysiologic examination that reflects brain cognition
function [25,26]. Related research has shown that pa-
tients with mild cognitive impairment exhibit changes in
P300 [27]. The P300 latency period reflects the evalu-
ation time of stimuli in cognitive activities, which is an
index for information processing speed [28], reflecting
to a certain degree the perception, attention, memory,
information coding, and cognitive integration speed brain
function state [29]. The results of this study show that the
P300 latency period in the VCIND group was significantly
longer than in the other two groups, which indicates
stable and high sensitivity of the P300 latency period and
the abnormalities during mild cognitive impairment. Cor-
relation analysis shows that the tHcy level in the VCIND
group is positively correlated with the P300 latency period,
which further supports the association of tHcy levels with
impaired cognition.Conclusions
VCIND patients have significantly higher levels of tHcy
and lower levels of vitamin B12 and folate. The increased
tHcy in VCIND patients may be related to cognitive im-
pairment, which provides a possibility for the treatment
of tHcy levels to improve cognitive function in VCIND
patients, which should be confirmed in future research
work.
This study mainly selected the elderly as the research
subjects, and the sample size was relatively small, which
might be the limitation of this study. This study also did
not consider the effect of folate and vitamin B12 directly
on cognitive function. Therefore, we recommended in-
creasing the number of cases and the statistical process-
ing methods in future studies for a more reliable
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